SciELO - Scientific Electronic Library Online

 
vol.42 número6Análisis de impacto presupuestario del implante intravítreo de dexametasona para el tratamiento del edema macular diabéticoRecomendaciones de la Sociedad Española de Farmacia Hospitalaria, la Sociedad Española de Enfermería Oncológica y la Sociedad Española de Oncología Médica para el manejo seguro de la medicación antineoplásica del paciente con cáncer índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

Links relacionados

  • Em processo de indexaçãoCitado por Google
  • Não possue artigos similaresSimilares em SciELO
  • Em processo de indexaçãoSimilares em Google

Compartilhar


Farmacia Hospitalaria

versão On-line ISSN 2171-8695versão impressa ISSN 1130-6343

Resumo

GINESTAL-LOPEZ, Ricardo Constantino. Immunotherapy for neurological diseases, present and future. Farm Hosp. [online]. 2018, vol.42, n.6, pp.251-260.  Epub 09-Nov-2020. ISSN 2171-8695.  https://dx.doi.org/10.7399/fh.11031.

Objective:

The objective of this work is to summarize the immunological treatment of neurological diseases, describing the present situation and the challenges and opportunities the future will present.

Method:

After topographically classifying the autoimmune neurological pathologies, a bibliographic analysis is made to present the most relevant ones regarding the available immunotherapeutic options. Likewise, new neurological entities that will be future candidates for immunotherapy are discussed.

Results:

There is a large number of neurological diseases with an autoimmune basis, even though their pathophysiology is, sometimes, only partially understood. Only a few randomized controlled clinical trials support the evidence of the immunotherapies with which we treat some of these diseases. This situation is rapidly changing among entities like multiple sclerosis where level 1 of evidence clinical studies are today´s standard. Alzheimer´s disease and migraine are two of the most prevalent conditions that are being incorporated to the group of diseases candidates for immunotherapy.

Conclusions:

Taking into account the rapidly growing number of immunological therapies and of neurological diseases potentially receiving them, an adequate evaluation of the impact these treatments will have on social and healthcare system grounds is necessary to reach compromises and consensus among all the professionals involved in the management of these pathologies.

Palavras-chave : Immunotherapy; Neurologic disorders; Autoimmune diseases; Multiple sclerosis; Neuromyelitis optica; Alzheimer disease; Migraine; Movement disorders.

        · resumo em Espanhol     · texto em Inglês | Espanhol     · Inglês ( pdf ) | Espanhol ( pdf )